利润年均增长54%，乙肝终结者的生意经！

Core Viewpoint - The article highlights a significant advancement in the treatment of chronic hepatitis B in China, with the approval of Pegbelfermin for the functional cure of hepatitis B, marking a shift from merely controlling the virus to achieving clinical cure [4][5]. Group 1 - There are approximately 75 million chronic hepatitis B patients in China [4]. - The long-standing treatment goal for hepatitis B has been to "control the virus" by suppressing the replication of hepatitis B virus DNA, without clearing the hepatitis B surface antigen (HBsAg) [4]. - In October 2025, Pegbelfermin, in combination with nucleos(t)ide analogs, received approval from the National Medical Products Administration for the new indication of sustained HBsAg clearance in adult chronic hepatitis B patients [4]. Group 2 - Sustained clearance of HBsAg, commonly referred to as "clinical cure" for hepatitis B, is now achievable [5]. - Pegbelfermin is the first drug approved for this indication, signifying a new phase in hepatitis B treatment in China, transitioning from "viral control" to "functional cure" [5].